Ledertrexate

Methotrexate Disodium, the active ingredient in Ledertrexate, is an antimetabolite presented as a sterile injectable for intraarterial, intracardiac, and intramuscular use. It is employed in the management of autoimmune disorders and certain cancers, targeting abnormal cell proliferation.

GNH USA supplies Ledertrexate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.

Ledertrexate is a methotrexate formulation used across several disease families, primarily autoimmune and malignant conditions.

- Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: diminishes skin lesions and curtails plaque formation. - Acute lymphoblastic leukemia: interferes with leukemic cell replication to achieve remission. - Non‑Hodgkin lymphoma: impedes malignant lymphocyte growth as part of combination therapy. - Gestational trophoblastic disease: promotes resolution of abnormal trophoblastic tissue.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea and vomiting - Oral ulceration or mucositis - Fatigue or malaise - Alopecia (hair loss) - Elevated liver enzymes - Mild skin rash

Serious or Rare Side Effects: - Bone marrow suppression leading to pancytopenia - Severe hepatic toxicity or fibrosis - Pulmonary fibrosis or interstitial pneumonitis - Acute renal failure - Life‑threatening infections due to immunosuppression - Teratogenic effects causing fetal malformations

Careful monitoring and patient education are essential when using Ledertrexate. - Blood count monitoring: perform complete blood counts regularly to detect marrow suppression. - Liver function assessment: evaluate hepatic enzymes before and during therapy. - Renal function evaluation: adjust dosing if creatinine clearance is reduced. - Pregnancy avoidance: contraindicated in pregnancy; ensure effective contraception. - Contraception counseling: advise both male and female patients on reliable methods. - Store at ambient temperature: keep in original container, protect from moisture and light.

Methotrexate Disodium has notable drug interactions that require attention.

Major Interactions (Avoid): - NSAIDs: increase risk of gastrointestinal toxicity and renal impairment. - Penicillins: may reduce methotrexate clearance, raising systemic exposure. - Sulfonamides: potentiate bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Azathioprine: additive immunosuppressive effect, monitor blood counts. - Cyclosporine: can elevate methotrexate plasma levels, adjust dose as needed. - Trimethoprim: may increase renal toxicity, observe renal function.